Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14376386 | 0.85 | MEN1 (0.58) | PDGFRBRPS6KA3 | |
| SCHEMBL14376565 | 0.82 | TLK2 (0.64) | RETLRRK2PDGFRBRPS6KA3MDM2 | |
| SCHEMBL14375877 | 0.81 | SRC (0.47) | RETPDGFRBEGFR | |
| SCHEMBL14375845 | 0.81 | RET (0.62) | RETLRRK2PSEN1PSEN2APH1B | |
| SCHEMBL14375848 | 0.80 | LRRK2 (0.68) | RETLRRK2PDGFRBRPS6KA3MDM2 | |
| SCHEMBL14375850 | 0.80 | TLK2 (0.52) | RETLRRK2PSEN1PSEN2APH1B | |
| SCHEMBL14375876 | 0.79 | RET (0.65) | RETLRRK2TGM2PDGFRBRPS6KA3 | |
| SCHEMBL15879182 | 0.79 | NPC1 (0.69) | RETLRRK2PSEN1PSEN2APH1B | |
| SCHEMBL14375860 | 0.79 | NPC1 (0.69) | RETLRRK2PSEN1PSEN2APH1B | |
| SCHEMBL14376382 | 0.77 | RET (0.55) | RETLRRK2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | RET 789/4885LRRK2 1/4885PSEN1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.